Research programme: short interfering RNA-based therapeutics - Silence Therapeutics

Drug Profile

Research programme: short interfering RNA-based therapeutics - Silence Therapeutics

Alternative Names: GalNAc-siRNA - Silence Therapeutics; ICS-283; Research programme: RNAi-based therapeutics -Intradigm/Qiagen; SLN-124

Latest Information Update: 27 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intradigm Corporation
  • Developer Intradigm Corporation; OPKO Health; Silence Therapeutics
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Iron overload
  • Research Acromegaly; Alcoholism; Cardiovascular disorders; Metabolic disorders
  • Discontinued Age-related macular degeneration; Cancer; Coronavirus infections; Diabetic retinopathy

Most Recent Events

  • 26 Mar 2018 Preclinical trials in Iron overload in United Kingdom (Parenteral) before March 2018 (Silence Therapeutics pipeline, March 2018)
  • 06 Mar 2018 Silence Therapeutics plans to initiate a clinical trial of SLN 124 by the end of 2018
  • 17 Jan 2018 Silence Therapeutics has patent protection for siRNA chemical modifications in European union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top